Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GRFS
stocks logo

GRFS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
1.88B
+3.63%
--
--
1.86B
+3.65%
--
--
1.94B
-1.7%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Grifols, S.A. (GRFS) for FY2025, with the revenue forecasts being adjusted by 0.09% over the past three months. During the same period, the stock price has changed by -12.24%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.09%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-7.7%
In Past 3 Month
Stock Price
Go Down
down Image
-12.24%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Grifols SA (GRFS.O) is 7.50, compared to its 5-year average forward P/E of 16.68. For a more detailed relative valuation and DCF analysis to assess Grifols SA 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
16.68
Current PE
7.50
Overvalued PE
23.46
Undervalued PE
9.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Undervalued
5Y Average EV/EBITDA
12.10
Current EV/EBITDA
4.59
Overvalued EV/EBITDA
14.83
Undervalued EV/EBITDA
9.37

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
1.30
Current PS
0.81
Overvalued PS
1.92
Undervalued PS
0.68
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 986.97% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

GRFS News & Events

Events Timeline

(ET)
2025-11-04
11:54:39
Grifols announces Q3 adjusted EBITDA of EUR 482M, reflecting an 8.8% increase in constant currency.
select
2025-07-29 (ET)
2025-07-29
12:48:43
Grifols affirms 2025 guidance from capital markets day
select
2025-07-29
12:47:22
Grifols reinstates dividend of EUR 0.15 per share
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-26NASDAQ.COM
Daily Upgrade Report for Validea's Joseph Piotroski Strategy - November 26, 2025

  • Validea's Upgrades: Today's upgrades for Validea's Book/Market Investor model highlight significant changes in ratings for stocks like Grifols SA, Invesco Ltd, and Molson Coors Beverage Co, reflecting improved fundamentals and valuations.

  • Grifols SA: The stock rating for Grifols SA increased from 0% to 90%, indicating strong interest based on its financial health and valuation in the biotechnology sector.

  • Invesco Ltd: Invesco Ltd's rating improved from 0% to 80%, suggesting a positive outlook based on its fundamentals in the investment services industry.

  • Molson Coors Beverage Co: Molson Coors Beverage Co saw its rating rise from 0% to 90%, demonstrating strong interest due to its financial performance in the alcoholic beverages market.

[object Object]
Preview
4.0
10-10NASDAQ.COM
Daily Upgrade Report for Validea's Joseph Piotroski Strategy - October 10, 2025

  • Validea's Upgrade: Validea's Book/Market Investor model, based on Joseph Piotroski's strategy, upgraded Grifols SA (GRFS) from 0% to 90%, indicating strong interest due to improved fundamentals and stock valuation.

  • Company Overview: Grifols SA is a Spanish pharmaceutical company specializing in plasma-derived medicines, organized into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others, focusing on both therapeutic and non-therapeutic biological products.

[object Object]
Preview
4.0
08-28NASDAQ.COM
Everything You Should Know About Grifols (GRFS) Upgrade to Buy Rating

  • Grifols Upgrade: Grifols (GRFS) has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook on its earnings estimates, which can influence stock prices.

  • Earnings Estimates Impact: The Zacks rating system focuses on changes in earnings estimates, which are strongly correlated with near-term stock movements, making it a valuable tool for investors.

  • Analyst Consensus: Over the past three months, analysts have raised their earnings estimates for Grifols, reflecting an improvement in the company's underlying business and potential for stock price increase.

  • Zacks Rating System: The Zacks Rank system categorizes stocks based on earnings estimate revisions, with only the top 20% receiving "Strong Buy" or "Buy" ratings, suggesting that Grifols is positioned for market-beating returns.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Grifols SA (GRFS) stock price today?

The current price of GRFS is 8.89 USD — it has increased 1.25 % in the last trading day.

arrow icon

What is Grifols SA (GRFS)'s business?

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.

arrow icon

What is the price predicton of GRFS Stock?

Wall Street analysts forecast GRFS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRFS is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Grifols SA (GRFS)'s revenue for the last quarter?

Grifols SA revenue for the last quarter amounts to 2.14B USD, increased 9.52 % YoY.

arrow icon

What is Grifols SA (GRFS)'s earnings per share (EPS) for the last quarter?

Grifols SA. EPS for the last quarter amounts to 0.19 USD, increased 850.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Grifols SA (GRFS)'s fundamentals?

The market is revising Upward the revenue expectations for Grifols, S.A. (GRFS) for FY2025, with the revenue forecasts being adjusted by 0.09% over the past three months. During the same period, the stock price has changed by -12.24%.
arrow icon

How many employees does Grifols SA (GRFS). have?

Grifols SA (GRFS) has 23833 emplpoyees as of December 05 2025.

arrow icon

What is Grifols SA (GRFS) market cap?

Today GRFS has the market capitalization of 6.05B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free